News
MedPage Today on MSN2d
Zepbound and Wegovy Go Head to Head for Obesity: And the Winner Is ...Tirzepatide (Zepbound) came out on top against semaglutide (Wegovy) for treating obesity in the head-to-head SURMOUNT-5 trial ...
CVS Caremark decided to stop offering Zepbound in favor of Wegovy for weight loss. It’s the latest example of limits imposed ...
Eli Lilly’s obesity drug Zepbound led to nearly 50 percent more weight loss than Novo Nordisk’s Wegovy in the first direct ...
With Zepbound at Its Core, The Naderi Center's New Initiative Addresses Male Weight Loss and Facial Rejuvenation Through ...
InvestorsHub on MSN1d
Novo Nordisk Inks $2.2 Billion Deal with Septerna to Advance Obesity and Diabetes TreatmentsNovo Nordisk (NYSE: NVO) has entered into a collaboration and licensing agreement with U.S.-based biotech firm Septerna ...
Zacks Investment Research on MSN3h
Septerna Stock Surges on Oral Obesity Drug Deal With Novo NordiskShares of Septerna SEPN surged 51% on May 14 after the company entered into an exclusive global collaboration and license ...
In addition to eliciting greater weight loss than Novo Nordisk’s Wegovy, Eli Lilly’s Zepbound does not come at the expense of ...
President Trump said he would sign an executive order to base U.S. drug prices on what other countries pay — usually far less ...
Results that may be inaccessible to you are currently showing.
Hide inaccessible results
Feedback